GH axis
Growth hormone axis peptides
Releasing hormone analogues, secretagogues and growth factor variants for GH axis work.
Two molecular classes in one section
The section holds two quite different kinds of molecule, and telling them apart is the first thing worth doing.
Releasing hormone analogues are long chains modelled on a hypothalamic releasing hormone. They run to twenty nine residues and beyond, and they bind a class B1 G protein coupled receptor in two parts, the back of the chain anchoring to the extracellular domain and the front end reaching into the helical bundle. Sermorelin at 3357.9 g/mol, CJC-1295 (no DAC) at 3367.9, CJC-1295 DAC at 3647.2 and Tesamorelin at 5135.9 all sit here.
Secretagogues are built on a different plan: five or six residues, a receptor of a different class, and residues that no ribosome assembles. Ipamorelin is written Aib-His-D-2Nal-D-Phe-Lys-NH2, which packs an unnatural residue, two D amino acids and a capped C terminus into a chain of 711.9 g/mol. GHRP-2 at 817.9, GHRP-6 at 873 and Hexarelin at 887 are of the same compact type. Residues of that kind are not what a peptidase is built to cut, which is part of why the design reaches for them.
Modifications that change behaviour in solution
Two entries in this section exist in a plain and a modified version, and that modification is the reason both are catalogued. CJC-1295 carries, in one version, a group that reacts with thiols, which rules out reducing agents in the solvent. PEG-MGF carries a polyethylene glycol chain on MGF, which raises the apparent size of the molecule, changes how readily it dissolves and how it runs on a column, and turns a mass measurement into a distribution rather than a single sharp number. Neither modification changes how the vial is opened, but both change what should go into it. Choose the solvent first: bacteriostatic water for a vial sampled repeatedly, sterile water where no additive may be present.
What the section holds
Eighteen catalogue entries, all lyophilised in sealed vials. Four releasing hormone analogues: Sermorelin, Tesamorelin, CJC-1295 (no DAC) and CJC-1295 DAC. Four secretagogues: Ipamorelin, GHRP-2, GHRP-6 and Hexarelin. Two vials holding two components each: CJC-1295 (no DAC) + Ipamorelin and Tesamorelin + Ipamorelin. Three growth factor variants: IGF-1 LR3, MGF and PEG-MGF, the first of these in 0.1 mg and 1 mg fills. Three larger constructs: ACE-031, GDF-8 (Myostatin) and Follistatin 344. And two gonadotrophin releasing hormone analogues of the same ten residue build, Gonadorelin at 1182.3 g/mol and Triptorelin at 1311.5.
Release follows one rule across the section, described under quality. These are chemical reagents: not medicinal products, not food, not cosmetics, and not intended for consumption or for administration to humans or animals. Disposal and local handling follow the rules of your institution and the country you work in. The terms of supply are set out under research use only.
Frequently asked questions
What separates CJC-1295 DAC from CJC-1295 (no DAC)?
An added group, and the recorded masses show it: 3647.2 g/mol against 3367.9 g/mol for the plain chain. That group is built to form a covalent bond with a free thiol, so a buffer carrying a reducing agent, free cysteine or any other thiol is the wrong liquid to put it in. The plain chain carries no such reactive group and is handled like any other releasing hormone analogue in this section.
Does a 5 mg vial hold the same number of molecules everywhere in this section?
No, and the gap is large. Ipamorelin is recorded at 711.9 g/mol, so 5 mg is close to 7 micromoles. Sermorelin is recorded at 3357.9 g/mol, so the same 5 mg is close to 1.5 micromoles. The two classes in this section differ several fold in mass, which carries straight into any molar concentration you calculate. Divide the fill weight by the molar mass before planning volumes, or let the concentration calculator do it.
How are the smallest fills, 0.1 mg and 1 mg, best handled?
At that scale the solid is barely visible and nothing should be transferred as a powder. Add the solvent to the vial it arrived in, let it stand, swirl rather than shake, and split the solution into single use portions straight away, because at low concentration a measurable share of the material can settle on the walls of whatever holds it. Record the volume you added on the vial, since the glass keeps no account of it.